Investigational drug · Phase 3
Insuline glargine U100
Also called: reduced, titrated
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Relapsed/Refractory Acute Myeloid Leukaemia, Myeloid Malignancy, Diabetes Mellitus, Type 2.
Phase 3Last checked: Nov 20, 2026Latest source record: May 11, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
1 still active
All registered trials
1
Any phase or sponsor naming "Insuline glargine U100"
First trial start
2020
Sep 28, 2020
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Insuline glargine U100", any sponsor or status.
Conditions studied
As listed on its trial records.
- Relapsed/Refractory Acute Myeloid Leukaemia
- Myeloid Malignancy
- Diabetes Mellitus, Type 2
- Obesity
Approved drugs for the same conditions: Obesity and weight management · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "Insuline glargine U100" as an intervention, largest first.
- A Research Study to Look Into How Semaglutide, Together With a Lower Dose of Insulin Glargine, Compares to a Higher Dose of Insulin Glargine Alone in People With Type 2 Diabetes (SUSTAIN OPTIMIZE)Pivotal-lookingCompleted
Novo Nordisk A/SNovo Nordisk (NVO)
NCT05514535 · 573 participants · Start Aug 29, 2022 · Primary completion Mar 5, 2025
Drug: Semaglutide; Insuline glargine U100 (reduced) and 1 more · For: Diabetes Mellitus, Type 2; Obesity
Sites: Sheffield, Alabama; Glendale, Arizona; Mesa, Arizona · 239 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Association Between the Expiration of Supplemental Nutrition Assistance Program Emergency Allotments and Child Maltreatment.
Zhang L, Wang Y, Ma R, et al. · Am J Prev Med 2028
- Aortic stiffness and brain perfusion: a population-based study.
Gardarsdottir M, Sigurdsson S, Forsberg L, et al. · Scand Cardiovasc J 2027
- Microstate-specific functional connectivity in alcohol use disorder using resting-state EEG.
Park H, Yoo SY, Lee H, et al. · Dialogues Clin Neurosci 2027
- Effects of xylooligosaccharide supplementation on methane emissions, rumen microbiome, and serum metabolome in lactating Jersey cows.
Zhou X, Zhao Z, Zhao L, et al. · Anim Biotechnol 2027
- Comparative efficacy of topical garlic extract and 20% podophyllin solution in the treatment of female genital warts: a triple-blind randomized clinical trial.
Naseri M, Sarfallah Z, Saadat M, et al. · J Dermatolog Treat 2027
- 2026 iCARDIO Alliance Global Implementation Guidelines on Heart Failure.
Chopra V, Abraham WT, Amir O, et al. · J Card Fail 2027
Also in development for Relapsed/Refractory Acute Myeloid Leukaemia
- APG-2575lisaftoclaxPhase 310 trials
Ascentage Pharma Group Inc. · CLL/SLL, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
- OlverembatinibPhase 34 trials
Ascentage Pharma Group Inc. · Ph+ ALL, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive, Relapsed/Refractory Acute Myeloid Leukaemia
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.